Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

endomedic d.o.o., zagreb - ultrazvučni dijagnostički uređaj sa doplerom u boji

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

alfamedic d.o.o. vajdin vijenac 20 10000 zagreb -

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

alfamedic d.o.o. vajdin vijenac 20 10000 zagreb -

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

alfamedic d.o.o. vajdin vijenac 20 10000 zagreb -

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

alfamedic d.o.o. vajdin vijenac 20 10000 zagreb -

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

alfamedic d.o.o. vajdin vijenac 20 10000 zagreb -

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

alfamedic d.o.o. vajdin vijenac 20 10000 zagreb -

Europska Unija - hrvatski - EMA (European Medicines Agency)

instituto grifols s.a. - imunoglobulina osoba normalan - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - imuni serumi i homologna, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Europska Unija - hrvatski - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - prekursorska stanica limfoblastične leukemije-limfom - antineoplastična sredstva - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Europska Unija - hrvatski - EMA (European Medicines Agency)

merck sharp & dohme b.v. - letermovir - infekcije citomegalovirusa - antivirusni lijekovi za sustavnu uporabu - prevymis je indiciran za profilaksu citomegalovirus (cmv) reaktivacije i bolesti u odraslih cmv seropozitivne primatelja [r +] transplantacija alogenih krvotvornih matičnih stanica (hsct). treba uzeti u obzir formalne preporuke za odgovarajuće korištenje antivirusnih lijekova.